Dare Bioscience, INC 10-Q quarterly reports

Dare Bioscience reported a significant net loss and increased cash burn in Q3 2025, raising substantial doubt about its ability to continue as a going concern, despite strategic pivots and new grant funding.

Dare Bioscience, a women's health biopharmaceutical company, reported a significant net loss and cash burn in Q2 2025, raising going concern doubts, but has secured substantial post-period capital and grant funding.

Dar Bioscience reports Q1 2025 results, highlighting a net loss and going concern uncertainty, while expanding its business strategy to include Section 503B compounding.

Dare Bioscience's Q3 2024 results show a net loss, but the company's year-to-date financials are positively impacted by a significant royalty sale, while the company continues to advance its women's health product pipeline.

Dare Bioscience reports a net income of $12.9 million for the three months ended June 30, 2024, a significant turnaround from a net loss in the same period last year, primarily due to a royalty monetization transaction.

Dar Bioscience reports a net loss of $6.8 million for Q1 2024, highlighting ongoing financial challenges and the need for additional capital.